CVS Health program takes aim at ‘me-too’ drugs it deems not cost-effective
The PBM will incorporate cost-per-QALY analyses from ICER, but the program also drew some criticism.
Precision Health Economics
The PBM will incorporate cost-per-QALY analyses from ICER, but the program also drew some criticism.